Baiji Shenzhou teamed up with ASMB to develop a new type of hepatitis B drug.

Yesterday, Baiji Shenzhou announced that it will acquire Assembly Biosciences' hepatitis B core protein inhibitors ABI-H0731, ABI-H2158, and ABI-H3733 business interests in China and Hong Kong, Macao and Taiwan for a down payment of US$40 million and a potential mileage of US$500 million, while ASMB retains interests in other parts of the world.
Baiji Shenzhou will be responsible for the development, drug registration, and commercial promotion in China.
ABI-H0731, ABI-H2158 has started Phase 2 clinical phase, while ABI-H3733 is still in Phase 1 clinical phase.
hepatitis B virus is an ancient virus that may have existed in prehistoric times.
hepatitis B virus is one of the simplest viruses, with only 3000 base pairs, but can infect many species.
hepatitis B virus mutation is very fast, but the sequence of life can reproduce is relatively stable, according to the analysis of 7000 years ago hepatitis B virus and today's popular sequence is basically the same.
hepatitis B virus can only infect liver cells, unlike the new crown everywhere trouble.
theory such a stable sequence, single-minded infection target virus should be relatively easy to remove, but hepatitis B virus also has a unique life.
hepatitis B virus is a DNA virus that, when entered into the nucleus, is formed by the host DNA repair system as a broken DNA and a ring-shaped DNA (cccDNA).
this cccDNA is very stable, hidden in the nucleus as a template for viral mRNA, is the main cause of hepatitis B incurable cure.
h-B DNA can also be incorporated into the host genome, but these DNA cannot reproduce new hepatitis B virus.
90% of acute hepatitis B infections can be self-removed, similar to the new crown.
but who can self-eliminate hepatitis B, who will turn into chronic infections is not yet completely clear.
is more certain that the natural immune system, the immune system of the dayafter T, B cells are very important, but the specific component deficiency causes chronic hepatitis B is still under study.
existing antiviral drugs can effectively inhibit the spread of viruses, but the surface antigen transyang rate is very low.
interferon transyang rate is slightly higher, and the combination with antiviral drugs can be increased to about 10%.
now the most promising hepatitis B drug is the RNAi drug that targets several mRNAs, which can have a transcurrent rate of more than 10% on the other.
a Canadian company's non-specific RNA technology produces 50% surface antigen transceogenic rate in early clinical use, and if validated in large trials, it will be a breakthrough.
core proteins are critical to the synthesis of viral DNA from pgRNA, and ASMB's drugs interfere with this step of the response.
this is a relatively new type of hepatitis B drug, although may be to a certain extent to block the supply chain of hepatitis B but hepatitis B surface antigen transyang or the removal of cccDNA how much effect is not good to say.
antiviral drugs can effectively control the spread of the virus, but once discontinued there is a risk of rebound.
the main reason why most acute hepatitis B infection can self-rehabilitate may still be the credit of the immune system, unfortunately the hepatitis B immune escape mechanism is not clear, difficult to accurately alleviate poverty.
hopes that now clinically TLR, RIG-1, PD-1 and other drugs can step on a major switch, so that 10% of chronic hepatitis B patients back into the revolutionary family.
of course, these drugs, which inhibit viral reproduction, may also make it easier for the immune system to organize their tissues if they significantly reduce viral load, and combination therapy may be the future direction.
Although the hepatitis B vaccine is very effective, but unfortunately, there are still many people for various reasons not vaccinated.
chronic hepatitis B is still one of the world's largest chronic diseases, with an estimated 250-300 million patients worldwide.
although hepatitis B does not encode any cancer-causing proteins, but long-term infection will cause chronic inflammation and indirectly induce the occurrence of liver cancer, it is estimated that about 50% of liver cancer patients are chronic hepatitis B.
liver cancer is one of the relatively difficult to treat tumors, is the last few decades the mortality rate has been reduced the least solid tumor, so if the cure of hepatitis B can greatly relieve the pressure of liver cancer.
China is a high incidence of hepatitis B, Chinese enterprises to participate in the development of new mechanism hepatitis B drugs is a good thing to encourage.
.